Table 3

Immunohistochemical scoring (mean) of the primary tumor in IL-12-treated (n = 9) and control patients (n = 20)

MarkerCell typeNo. categoriesSite in tumorIL-12 treated mean (SD), n = 9Control mean (SD), n = 20P
CD3T cell3Intratumoral1.6 (1.0)1.7 (0.9)
3Peritumoral1.8 (1.0)1.8 (0.8)
CD4T helper cell5Overall2.7 (0.8)2.6 (1.0)
CD8T cytotoxic cell5Intratumoral1.6 (1.2)2.0 (1.1)
5Peritumoral2.3 (1.0)2.3 (0.9)
CD20B cell5Intratumoral1.8 (1.0)1.8 (1.2)
5Peritumoral2.6 (1.0)1.7 (1.0)0.06
CD79aB cell and plasma cell5Intratumoral1.9 (0.9)2.2 (0.8)
5Peritumoral2.0 (1.2)1.4 (0.6)
CD56NK cell5Overall2.8 (0.9)1.6 (0.8)<0.01
CD57NK cell and subset of T cells5Intratumoral1.4 (1.1)1.2 (0.9)
5Peritumoral1.1 (1.0)1.2 (1.0)
CD68Macrophage3Intratumoral0.8 (0.4)1.3 (0.9)
3Peritumoral2.1 (0.6)2.1 (0.8)
More peritumoral1 (0)0.6 (0.5)<0.05
DRCDC (follicular)3In FDC0.6 (0.9)0.7 (0.7)
3In vessels0.4 (0.9)0.4 (0.6)
DC-SIGNDC immature5Overall2.7 (1.2)2.1 (0.9)
DC-LAMPDC mature5Overall1.8 (0.9)1.7 (0.8)
LangerinDC (Langerhans)5Overall1.8 (1.5)2.0 (1.2)
CD11cDC, granulocyte, macrophage5Overall2.4 (0.8)2.3 (0.8)
ICAM-2Endothelium5Vessel2.1 (0.9)1.9 (0.8)
Stromal5Stromal1.4 (0.8)1.9 (0.9)
ElastaseNeutrophil5Intratumoral1.6 (0.8)2.0 (0.9)
5Peritumoral0.9 (0.9)1.1 (1.1)
5In tumor cell groups1.0 (1.0)1.8 (1.4)
AA-1Mast cell3Overall1.8 (0.7)1.7 (0.7)
EG-2Eosinophil5Overall1.0 (0.7)1.9 (1.0)0.06
  • NOTE. Some markers were scored intratumorally and peritumorally, others only overall. More CD56+ NK cells were seen in the primary tumor after IL-12 treatment. In IL-12-treated patients, the majority of the CD68+ cells was located peritumorally.